Virbac to distribute new anticancer treatment for dogs
13 August, 2018Animal health company Virbac will market and distribute tigilanol tiglate, an anticancer pharmaceutical from QBiotics, to veterinary markets in the US, the UK and the EU.
Peptide drug could treat liver cancer more effectively
06 August, 2018A novel peptide drug called FFW could potentially stop the development of hepatocellular carcinoma (HCC), or primary liver cancer.
Drugging cancer cells to sleep
03 August, 2018Australian researchers have discovered a new type of anticancer drug that is said to be able to put cancer cells into a permanent sleep.
Could Australia's microbiome contain new antibiotics?
01 August, 2018Industry and academia are coming together in a three-year, $6.9 million quest to search for new antibiotics in 500,000 species of Australian microbes.
More effective chemo for lung cancer patients
31 July, 2018A naturally occurring hormone called follistatin could help make chemotherapy much more effective for lung cancer patients, while also preventing kidney damage.
Designer molecule targets cancer growth protein
20 July, 2018A new molecule designed by University of Adelaide researchers has successfully targeted a protein that plays a major role in the growth of most cancers.
Novotech partners with Asian Eye Institute to accelerate clinical trials
17 July, 2018Novotech works in partnership with leading medical institutions across Asia to accelerate quality clinical research.
Ultrasound used to burst chemo-capsules inside liver tumours
12 July, 2018Heat-sensitive lipid capsules filled with chemotherapy have been ruptured remotely using ultrasound, enabling them to deliver their cargo directly to liver tumours.
Enzymes enable faster, cheaper, more accurate DNA synthesis
27 June, 2018The idea of using an enzyme to make DNA is not new — scientists have been trying for decades to find a way to do it, without success.
Drug-carrying nanoparticles designed to treat brain cancer
12 June, 2018The newly developed nanoparticles are designed so that they can easily cross the blood-brain barrier and bind directly to tumour cells, where they deliver two different drugs.
Hope for hard-to-treat cancers as new drug goes on trial
06 June, 2018Professor Jiri Neuzil is leading clinical trials of the experimental drug MitoTam in patients with triple negative tumours, which are known to be very hard to treat.
Kidney disease trial shows two drugs are better than one
05 June, 2018 by Lauren DavisClinical-stage biotech company Dimerix is on a mission to treat chronic kidney disease and, with the help of lead therapeutic candidate DMX-200, it just might succeed.
Reengineering the immune system to kill cancer
28 May, 2018 by Mansi GandhiCAR-T immunotherapy has the potential to revolutionise the way certain cancers are treated but challenges associated with cost and complexity of these therapies have limited widespread adoption.
Bioengineers build better beta peptides
11 May, 2018For the first time, Australian scientists have shown it is possible to attach self-assembling beta peptides onto different organic molecules.
Small biotechs dominate in microbiome-targeted therapies
27 April, 2018With smaller biotech companies dominating the pipeline for microbiome-targeted therapeutics, large pharma firms are eager to jump on the bandwagon.
